The current communication is the first to describe immunophenotypic normalization of bone marrow mast cells in patients with systemic mastocytosis treated with imatinib mesylate. It is to be recalled that neoplastic mast cells are both morphologically (spindle-shaped and hypogranular vs round with abundant cytoplasmic granules) and immunophenotypically (CD117 þ / CD25 þ vs CD117 þ /CD25 À ) different from their normal as well as reactive counterparts. 6 The current case demonstrates the value of bone marrow histology enhanced with tryptase or CD117-based immunohistochemistry as well as bone marrow mast cell immunophenotyping in the monitoring of effective therapy in systemic mastocytosis. Imatinib for systemic mast-cell disease. In most CML patients, treatment with imatinib mesylate (Glivec), a specific ABL kinase inhibitor, leads to disappearance of the Ph chromosome; nevertheless, the long-term efficacy and toxicity profile of imatinib remain largely unknown. Intriguingly, over the last 2 years, several groups have demonstrated Ph (À) cytogenetically abnormal clones in patients with CML treated with imatinib, at a rate seemingly higher than the one observed with IFN-alpha.
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In our department, in a cohort of 35 CML patients treated with imatinib for a median duration of 16.0 months (range, 3-42 months), three patients developed novel chromosomal aberrations in Ph (À) cells as reported below.
Case 1
A 22-year-old male was diagnosed with CML in accelerated phase in December 2001. Cytogenetic analysis of bone marrow (BM) mononuclear cells revealed t(9;22) (q34;q11) in all metaphases tested. RT-PCR identified b3a2 chimeric BCR-ABL mRNA transcripts. The patient was initially given hydroxyurea; starting from March 2002, he was put on imatinib at 400 mg/ day. At 6 months on imatinib, he had attained complete hematological remission and a minimal cytogenetic response with 96% Ph( þ ) metaphases. Imatinib dose was then increased to 600 mg/day; at 14 months, cytogenetic analysis demonstrated major cytogenetic response (25.9% (7/27) Ph ( þ ) metaphases) concurrently with the appearance of a novel hypodiploid clone with monosomy 7 in 8/27 metaphases, all Ph (À); interestingly, there was also a Ph (À) metaphase with trisomy 8. FISH analysis confirmed isolated trisomy 8 and monosomy 7 in 6.5 and 29% of cells, respectively. Examination of BM aspirate and biopsy samples showed no evidence of myelodysplasia. The patient underwent allogeneic matched sibling hematopoietic cell transplantation in July 2003; he remains in complete hematological, cytogenetic and molecular remission.
Case 2
A 43-year-old female subject was diagnosed with CML in myeloid blast crisis (10% MPO þ CD34 þ BM blast cells; extramedullary myeloid tumor (chloroma) in cervical lymph nodes). Cytogenetic analysis of BM mononuclear cells demonstrated t(9;22) (q34;q11) in all metaphases tested, while RT-PCR identified b3a2 chimeric BCR-ABL mRNA transcripts. The patient entered a second chronic phase with one course of combination chemotherapy (October 2002) consisting of idarubicin (10 mg/m 2 i.v. over days 1, 3 and 5) and cytarabine (100 mg/m 2 in 24-h infusion over days 1-7); because of pulmonary aspergillosis, no further treatment was given until January 2003, when she was put on imatinib at 600 mg/day. Cytogenetic analysis before imatinib revealed 100% Ph ( þ ) metaphases. At 2 months, the percentage of Ph ( þ ) metaphases decreased to 76% (minor cytogenetic response), concurrently with the appearance of a novel, unrelated hyperdiploid clone with trisomy 8 in 5/25 metaphases, all Ph (À). A repeat analysis at 5 months showed 5% Ph ( þ ) metaphases (major cytogenetic response) and 13/20 Ph (À) metaphases with trisomy 8. FISH analysis showed trisomy 8 in 47.5% of analyzed cells. At 10 months, cytogenetic and FISH analysis of BM mononuclear cells demonstrated 6.6 and 6.92% Ph ( þ ) cells, respectively, and importantly disappearance of the clone with trisomy 8. The patient remains in complete hematological remission, without evidence for myelodysplasia on BM aspirate/biopsy examination.
Case 3
A 40 year-old male was diagnosed with CML in chronic phase in September 1996. Cytogenetic analysis demonstrated t(9;22) (q34;q11) in all metaphases tested, while RT-PCR identified b2a2 chimeric BCR-ABL mRNA transcripts. The patient attained complete hematologic response with hydroxyurea and then underwent autologous hematopoietic cell transplantation (AHCT, in July 1997), leading to minor cytogenetic response (37.5% Ph ( þ ) metaphases at 6 months after AHCT). Then, starting from January 1998, he was given interferon-alpha and 12 courses of per os cytarabine; nevertheless, the percentage of Ph ( þ ) metaphases gradually increased and eventually he developed hematologic relapse with 100% Ph ( þ ) cells. Imatinib mesylate is associated with very high cytogenetic response rates in patients with both chronic and accelerated phase CML; nevertheless, the long-term impact of this drug remains largely unknown. In this context, the emergence of cytogenetically abnormal Ph (À) clones raises several important questions. It is largely unknown whether novel chromosomal aberrations in Ph (À) cells are imatinib-induced, whether they could represent disease evolution, or they are a transient effect (vide case#2 of the present report) of unknown pathogenesis and significance.
Based on available evidence, novel chromosome aberrations are rarely seen in early chronic-phase CML patients or in patients treated with imatinib upfront.
2-8 Of the three patients reported herein, two were diagnosed in accelerated and blast phase, respectively, and required high doses of imatinib (600 mg); it is not unreasonable to speculate that such patients with a more aggressive form of the disease might be at a greater risk for development of novel genetic aberrations, possibly due to their smaller pool of Ph (À) progenitors. Case #3 is a heavily pretreated patient, who had proven resistant both to IFN-alpha and AHCT. Thus, it is possible that the patient's hematopoiesis had sustained genetic damages already before starting imatinib.
Most of the cytogenetic aberrations previously reported in Ph (À) cells after imatinib were trisomy 8 and monosomy 7 (À7/À7q).
2-8 The karyotypic abnormalities reported herein included one case each of trisomy 8, loss of chromosome Y and coexisting (albeit in distinct Ph (À) cells) trisomy 8 and monosomy 7. Trisomy 8 is very frequent in myeloproliferative disorders (including CML), while monosomy 7 is often observed in secondary AML/MDS. Isolated loss of the Y chromosome is frequently observed in healthy elderly males and in most cases should be accepted as a normal age-related phenomenon; importantly, however, our patient showed a progressive increase of -Y metaphases (from 16 to 27.2% in a period of only 3 months). Loss of Y chromosome is also frequently observed in myeloproliferative diseases, MDS and AML; furthermore, in both CML and AML, ÀY tends to occur at a younger age (as in our case) than in the general population. In AML, loss of Y chromosome is thought to have an intermediate prognosis; in MDS, the prognosis appears to be neutral or favorable; there are insufficient data for myeloproliferative diseases. 9 Importantly, during cytogenetic follow-up over a period of 4-8 months, none of our patients had morphologic features (on BM aspirate/biopsy examination) suggestive of MDS or AML. This is in keeping with the recent report by O'Dwyer et al, 3 who described clonal karyotypic abnormalities in Ph (À) cells in seven CML patients on imatinib: in that study, peripheral blood and BM morphology at baseline and at a median interval of 13 months after initiation of imatinib were not significantly different between patients with and without clonal aberrations in Ph (À) cells, especially with regard to dysplastic morphologic changes (mild dysplastic abnormalities were equally prevalent in both groups).
In conclusion, the true biological significance as well as the mechanism responsible for the emergence of novel chromosome aberration in Ph (À) cells of CML patients treated with imatinib is currently unknown; nevertheless, given potential clinical implications, a close follow-up of these cases is strongly recommended. Finally, our results further emphasize the value of classical cytogenetic monitoring of CML patients on imatinib, even after attainment of complete cytogenetic remission. Several variables have been previously identified as adverse risk factors for survival after HLA-identical sibling donor allogeneic stem cell transplantation (SCT). Indeed, advanced phase of disease is associated with increased relapse rate and death due to leukemia progression. On the other hand, factors influencing the incidence and severity of graft-versus-host disease (GvHD), such as sex mismatch (female donor and male recipient), older recipient age or positive CMV serology, are related to an increased transplant-related mortality.
1,2 However, it is sometimes difficult to know the real impact of these risk factors on transplant outcome when considering a single patient, because favorable and adverse conditions may be present at the same time. In this work, we present a clinical score for predicting the survival of allogeneic SCT from HLA-identical sibling donors for myeloid malignancies on the basis of the evaluation and grading of risk factors available pretransplant.
We retrospectively analysed the pretransplant data and the clinical post-transplant outcome for 319 adult patients diagnosed of acute myeloid leukemia (AML) (n ¼ 150) or CML (n ¼ 169) who received an allogeneic SCT from an HLAidentical sibling donor from 1991 to 2002, performed in 14 centers. Patients with AML were assigned to the following FAB groups: M0: 3%; M1: 15%; M2: 24%; M3: 6%; M4: 25%; M5: 18%; M6: 3%; M7: 1%; post-MDS: 5%. The median follow-up for living patients was 2.8 years (range: 3 months-13 years). All the patients were older than 15 years and conditioned with myeloablative regimens.
Patients with AML beyond first complete remission and CML beyond first chronic phase were considered as with an advanced phase of disease. We considered sex mismatch as a female donor and a male recipient. GvHD was diagnosed and 
